Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01433237
First received: September 9, 2011
Last updated: May 8, 2015
Last verified: May 2015
  Purpose

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.


Condition Intervention
Sarcoma
Genetic: RNA analysis
Genetic: gene expression analysis
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Serum miR-206 as a biomarker for RMS [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: September 2011
Estimated Primary Completion Date: January 2100 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS).

OUTLINE: Archived serum samples are analyzed for miR-206 expression.

PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS.

Criteria

DISEASE CHARACTERISTICS:

  • Serum specimens of rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS available from the Soft Tissue Sarcoma committee of Children's Oncology Group

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01433237

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Hajime Hosoi, MD Kyoto Prefectural University of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT01433237     History of Changes
Other Study ID Numbers: ARST12B1, COG-ARST12B1, ARST12B1, NCI-2011-03457
Study First Received: September 9, 2011
Last Updated: May 8, 2015
Health Authority: United States: Federal Government

Keywords provided by Children's Oncology Group:
embryonal childhood rhabdomyosarcoma
adult rhabdomyosarcoma
alveolar childhood rhabdomyosarcoma
adult soft tissue sarcoma
childhood rhabdomyosarcoma

Additional relevant MeSH terms:
Rhabdomyosarcoma
Myosarcoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Sarcoma

ClinicalTrials.gov processed this record on May 27, 2015